Literature DB >> 20510240

Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention.

Sougata Karmakar1, Jonathan Kay, Ellen M Gravallese.   

Abstract

In rheumatoid arthritis (RA), cells within the inflamed synovium and pannus elaborate a variety of cytokines, including tumor necrosis factor (TNF) alpha, interleukin (IL)-1, IL-6, and IL-17, that contribute to inflammation, and may directly affect bone. The receptor activator of NF-kappaB (RANK) ligand/RANK/osteoprotegerin pathway plays a critical role in regulating osteoclastogenesis in articular bone erosions in RA. Proinflammatory cytokines can modulate this pathway, and may also affect the ability of the osteoblast to repair bone at sites of articular erosion. In this review, the authors discuss the current understanding of pathogenic mechanisms of bone erosion in RA and examine current therapeutic approaches to prevent this damage.

Entities:  

Mesh:

Year:  2010        PMID: 20510240      PMCID: PMC2905601          DOI: 10.1016/j.rdc.2010.03.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  131 in total

1.  Healing of erosions in rheumatoid arthritis.

Authors:  T Sokka; P Hannonen
Journal:  Ann Rheum Dis       Date:  2000-08       Impact factor: 19.103

2.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 4.  The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass.

Authors:  M L Johnson
Journal:  J Musculoskelet Neuronal Interact       Date:  2004-06       Impact factor: 2.041

5.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

Review 6.  Matrix metalloproteinases: role in arthritis.

Authors:  Peter S Burrage; Kimberlee S Mix; Constance E Brinckerhoff
Journal:  Front Biosci       Date:  2006-01-01

7.  IL-1 mediates TNF-induced osteoclastogenesis.

Authors:  Shi Wei; Hideki Kitaura; Ping Zhou; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

8.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

9.  Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.

Authors:  M Chabaud; J M Durand; N Buchs; F Fossiez; G Page; L Frappart; P Miossec
Journal:  Arthritis Rheum       Date:  1999-05

10.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Authors:  E William St Clair; Désirée M F M van der Heijde; Josef S Smolen; Ravinder N Maini; Joan M Bathon; Paul Emery; Edward Keystone; Michael Schiff; Joachim R Kalden; Ben Wang; Kimberly Dewoody; Roberta Weiss; Daniel Baker
Journal:  Arthritis Rheum       Date:  2004-11
View more
  76 in total

1.  Cross-talk between T cells and osteoclasts in bone resorption.

Authors:  Lucia D'Amico; Ilaria Roato
Journal:  Bonekey Rep       Date:  2012-06-06

2.  Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.

Authors:  Dallas Jones; Laurie H Glimcher; Antonios O Aliprantis
Journal:  J Clin Invest       Date:  2011-07-01       Impact factor: 14.808

Review 3.  The osteoclast--what's new?

Authors:  Nicolas A Athanasou
Journal:  Skeletal Radiol       Date:  2011-08-17       Impact factor: 2.199

4.  FOXO1 deletion reduces dendritic cell function and enhances susceptibility to periodontitis.

Authors:  Wenmei Xiao; Guangyu Dong; Sandra Pacios; Maher Alnammary; Laura A Barger; Yu Wang; Yingying Wu; Dana T Graves
Journal:  Am J Pathol       Date:  2015-04       Impact factor: 4.307

Review 5.  Control of autoimmune inflammation by celastrol, a natural triterpenoid.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Brian Astry; Kamal D Moudgil
Journal:  Pathog Dis       Date:  2016-07-11       Impact factor: 3.166

6.  Linguistic validation into 20 languages and content validity of the rheumatoid arthritis-specific Work Productivity and Activity Impairment questionnaire.

Authors:  Jérémy Lambert; Brian B Hansen; Benoit Arnould; Géraldine Grataloup; Isabelle Guillemin; Lise Højbjerre; Martin Strandberg-Larsen; Margaret C Reilly
Journal:  Patient       Date:  2014       Impact factor: 3.883

7.  CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response.

Authors:  H Wang; J Zhao; H Zhang; Y Huang; S Wang; Q Tu; N Yang
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

8.  Osteoclast-Primed Foxp3+ CD8 T Cells Induce T-bet, Eomesodermin, and IFN-γ To Regulate Bone Resorption.

Authors:  Elena V Shashkova; Jahnavi Trivedi; Anna B Cline-Smith; Chloe Ferris; Zachary S Buchwald; Jesse Gibbs; Deborah Novack; Rajeev Aurora
Journal:  J Immunol       Date:  2016-06-20       Impact factor: 5.422

9.  Body composition in patients with rheumatoid arthritis is not different than healthy subjects.

Authors:  Servet Akar; İsmail Sarı; Abdurrahman Çömlekci; Merih Birlik; Fatoş Önen; Yiğit Göktay; Dinc Özaksoy; Nurullah Akkoç
Journal:  Eur J Rheumatol       Date:  2014-09-01

Review 10.  Immunometabolism in early and late stages of rheumatoid arthritis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Nat Rev Rheumatol       Date:  2017-03-31       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.